IP is often the most valuable thing your business owns — and one of the hardest things to value correctly. We've built our practice around it: 250+ valuations delivered, AFSL-licensed, and equipped for the cases most firms won't take on.
Standard valuation frameworks — for instance, EBITDA multiples — work well for traditional businesses. For IP-rich assets, they might produce the wrong answer.
The value of a patent portfolio, a proprietary platform, or a data asset depends on the strength of its legal protection, its commercial optionality, and the context in which it's being assessed.
Applying the wrong methodology doesn't just produce an inaccurate number. In a negotiation, it leaves value on the table.
We apply market, income, cost, and relief-from-royalty approaches — and cross-check the results. No single framework. No shortcuts.
Whether the reader is an investor, a corporate counterparty, a board, or a court, the report is calibrated to what they need to accept and act on the valuation.
Every assumption is stated, explained, and defensible. If the methodology is challenged, we can defend every step.
Most IP advisers don't hold an AFSL. We do — No. 563351. Fully compliant, professionally indemnified, legally defensible.
In a contested matter, we identified that the opposing adviser had applied a standard business valuation framework to a complex IP asset. We documented an independent valuation using the correct multi-methodology approach. The client's position was upheld.
This is what we mean by a defensible valuation.
When you're licensing IP to a major corporation, entering a joint venture with a multinational, or selling a platform to a listed acquirer — the other side has sophisticated advisers and a strong incentive to drive your valuation down.
An independent, AFSL-licensed IP valuation gives you a number you can defend and a credibility that signals you know what you're doing.
Getting the number right is step one. But when you're at the negotiating table with a major corporation or defending a position in a dispute — Sherwood can be there for the journey too. We fight for our clients. That's the Sherwood approach.
Comparable data — anchoring your valuation in real-world evidence.
Modelling future economic benefit with appropriate risk-adjustment.
Consideration of the R&D costs with respect to the technology.
Estimating the royalty payments the owner is relieved from paying because it owns the IP outright.
Simple, transparent, and fast. Most business valuations are completed within 14 days from kickoff.
A short, confidential conversation to understand your business and what you need. We'll confirm the right approach upfront. No obligation, no cost.
We send a concise, structured request. You share your financials and relevant documents at your own pace — we make it as straightforward as possible.
Our team prepares your valuation using the methodology best suited to your situation — built to hold up with buyers, investors, lawyers, or the ATO.
We walk you through the findings, answer every question, and deliver your final report — ready to use in your negotiation, meeting, or proceeding.
IP valuations delivered across biotech, medtech, digital health, advanced manufacturing, AI, deep tech, SaaS and professional services — for founders, research institutions, listed companies and government bodies.
"Sherwood's valuation work brought clarity and credibility at a critical moment. Their expert report helped resolve a long-standing shareholder dispute without the need for costly litigation. It was a game-changer."
"The valuation prepared by Anthony and the Sherwood team gave us real leverage in our Series A discussions. It was robust, defensible, and tailored to the reality of early-stage MedTech — exactly what we needed."
"We approached multiple firms, but most wouldn't touch our company due to its complexity. Sherwood not only took it on — they delivered a valuation that gave us a solid footing in debt negotiations."
Anthony Vago leads every engagement personally. Response within 24 hours. Strictly confidential. No obligation.
Early-stage and IP-rich company valuations are complex — but getting them right is critical. Our free guide explains how to navigate uncertainty, from rNPV to milestone-based modelling. Leave your email to receive Valuing the Unquantifiable.
As part of Sherwood Global Partners, we tap into a powerful international network of corporate finance experts, strategic partners, and investors — bringing global opportunity to every transaction.
Tell us a little about your situation and Anthony Vago will be in touch — confidential, no obligation. Prefer to talk? Call +61 492 280 220 or email anthony@sherwoodaustralia.com.au.
